Genomics, public health and developing countries: the case of the Mexican National Institute of Genomic Medicine (INMEGEN).
In 2004, the government of Mexico established the National Institute of Genomic Medicine (INMEGEN), to carry out disease-related genomic studies that will address national health problems and stimulate scientific and technological development by generating new commercial products and services in genomic medicine. Towards this end, INMEGEN is carrying out a large-scale genotyping project to map genomic variation within its own population. The initiative is expected to generate a key resource for local researchers to understand disease susceptibility and variation in drug responses, which will contribute to Mexico's goal of developing public health genomics - a field in which Mexico is proving to be a leader amongst emerging economies.
Séguin
Béatrice
B
Béatrice Séguin is also at the Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario M5S 3M2, Canada.
Hardy
Billie-Jo
BJ
Singer
Peter A
PA
Daar
Abdallah S
AS
D000047:Academies and Institutes; D003906:Developing Countries; D023281:Genomics; D008800:Mexico; D011634:Public Health